Product image of Megalotect Cp (Human Cytomegalovirus Immunoglobulin) supplied by GNH India

Megalotect Cp

Active Ingredient:
Human Cytomegalovirus Immunoglobulin
Origin:
EU

Megalotect Cp (Human Cytomegalovirus Immunoglobulin)

Human Cytomegalovirus Immunoglobulin, the active ingredient in Megalotect Cp, is an immunoglobulin presented as a sterile intravenous solution for intravenous use. It supplies passive immunity by delivering antibodies that neutralize human cytomegalovirus, helping to prevent or treat CMV infection in transplant recipients and other immunocompromised patients.

GNH India supplies Megalotect Cp as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and clinics worldwide. The company ensures quality assurance, regulatory compliance, and reliable cold‑chain logistics for this biologic product.

Manufacturer / TM Owner

Biotest Pharma Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Megalotect Cp, a cytomegalovirus‑specific immunoglobulin, is used to provide passive immunity against human cytomegalovirus (HCMV) infections.

  • Solid organ transplant prophylaxis: reduces the incidence of CMV disease in recipients of kidney, liver, heart or lung transplants.
  • Bone marrow transplant treatment: aids in the management of active CMV disease in hematopoietic stem cell transplant patients.
  • Immunocompromised patient prophylaxis: offers protection against CMV reactivation in individuals with severe immune deficiency.

How It Works

  • Human Cytomegalovirus Immunoglobulin supplies exogenous anti‑CMV antibodies that bind to viral envelope glycoproteins, preventing attachment and entry into host cells. By neutralizing circulating virus, the preparation limits viral replication and facilitates clearance by the reticuloendothelial system, thereby providing immediate, passive protection while the patient’s own immune response matures. The administered immunoglobulin also engages Fc receptors, enhancing opsonization and complement activation, which further contributes to viral elimination.

Side Effects

Megalotect Cp may be associated with infusion‑related reactions and immune‑mediated adverse events.

Common Side Effects

  • Fever
  • Chills
  • Headache
  • Nausea

Serious or Rare Side Effects

  • Anaphylaxis
  • Aseptic meningitis
  • Renal impairment

Precautions & Warnings

Before administering Megalotect Cp, consider the following precautions to ensure safe use.

  • Assess CMV serostatus: verify donor and recipient serology to determine need for prophylaxis.
  • Monitor infusion reactions: observe patient during and after infusion for fever, chills, or hypotension.
  • Contraindicate in IgA deficiency: avoid use in patients with known severe IgA deficiency due to risk of anaphylaxis.
  • Use cautiously in renal impairment: adjust volume and monitor renal function during therapy.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Megalotect Cp can interact with other medicines; awareness of major and moderate interactions helps manage risk.

Major Interactions (Avoid)

  • Concurrent administration of other blood products: may increase risk of volume overload and circulatory complications.
  • Co‑administration with live viral vaccines: passive antibodies can diminish vaccine efficacy.
  • Use with monoclonal antibodies targeting CMV: potential antagonistic effect on therapeutic activity.

Moderate Interactions (Monitor Closely)

  • Combination with systemic steroids: may mask infusion‑related symptoms, requiring closer observation.
  • Concomitant use of diuretics: monitor fluid balance and electrolytes due to added volume load.
  • Co‑administration with antiviral agents such as ganciclovir: may have additive antiviral effects, necessitating viral load monitoring.

Frequently Asked Questions

Megalotect Cp is a human cytomegalovirus immunoglobulin indicated for the prevention and treatment of CMV infection in patients undergoing solid organ or hematopoietic stem cell transplantation and in other individuals with compromised immune systems who are at risk of CMV disease.

The immunoglobulin provides passive immunity by delivering high‑titer anti‑CMV antibodies. These antibodies bind to viral particles, block attachment to host cells, neutralize infectivity, and promote clearance through opsonization and complement activation, offering immediate protection while the patient’s own immune response develops.

Dosing is individualized. The prescribing clinician determines the amount, frequency, and duration of Megalotect Cp based on the patient’s weight, transplant type, CMV serostatus, and clinical condition. No fixed regimen is provided in public information.

Safety data for Megalotect Cp in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by the treating physician.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Megalotect Cp provides passive antibody‑mediated protection, whereas antiviral agents such as ganciclovir or valganciclovir act by inhibiting viral DNA synthesis. Immunoglobulin can be used alone for prophylaxis or in combination with antivirals for treatment, offering a different mechanism that may reduce viral load while avoiding some drug‑specific toxicities.

Megalotect Cp must be stored refrigerated at 2 °C to 8 °C. Keep the vials in the original packaging, protect from light, and do not freeze or shake the product. Before use, allow the solution to reach room temperature if required by the administration protocol.

The product is given by intravenous infusion. The infusion rate and total volume are determined by the prescribing clinician, typically administered over a period of 30 minutes to several hours, with vital signs monitored before, during, and after the infusion.

Serious adverse events include anaphylactic or severe allergic reactions, aseptic meningitis, and renal impairment. Patients should be observed closely for signs of hypersensitivity, sudden drop in blood pressure, neurological symptoms, or worsening kidney function during and after infusion.

Megalotect Cp is contraindicated in individuals with a known severe IgA deficiency or a documented hypersensitivity to human immunoglobulin preparations. Caution is also advised for patients with unstable cardiovascular status or uncontrolled renal disease.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Human Cytomegalovirus Immunoglobulin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT